BRVEBraveheart Bio

US ExchangeHealth Care2026-08-06

Clinical-stage biopharma developing oral small-molecule cardiac myosin inhibitors for hypertrophic cardiomyopathy (HCM).

$18IPO price

$383MRaised

$29.8Day-1 close

12.22%Day-1 return

Clinical-stage biopharma developing oral small-molecule cardiac myosin inhibitors for hypertrophic cardiomyopathy (HCM).

Company description (source: StockAnalysis)

Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.

医疗健康生物医药心血管

51CFO read: CFO must master clinical-stage financial modeling, FDA development pathway capital planning, and biopharma capital efficiency.

Management details per the SEC prospectus.

Company profile SEC prospectus

Does your company need this kind of CFO?

51CFO is an investment banking team focused on the US market: US IPOs, reverse mergers, shell deals, SPAC and De-SPAC, SEC filings and post-listing follow-ons, run by one team from structure to opening bell. Free 30-minute listing-route diagnosis, answered within 24 hours.

Talk to us